Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer
Conditions: Pancreatic Cancer; Pancreatic Cancer Non-resectable; Pancreatic Ductal Adenocarcinoma, PDAC Interventions: Drug: surufatinib combined with gemcitabine plus nab-paclitaxel Sponsors: Wuhan Union Hospital, China Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | China Health | COVID-19 | Hospitals | Pancreas | Pancreatic Cancer | Research